An interventional study of Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence Low->High) and Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence High->Low) in Pre-hypertension, sponsored by University of Bologna. Status unknown at 1 site in Italy. Open to participants aged 45 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-28.
Sponsored by University of Bologna · Not applicable, Interventional, and Treatment
In this study we will assess the effects of bioactive peptide rich wheat products on blood pressure and estimated cardiovascular disease risk. This will be a pilot, explorative, cross-over, randomized double-blind 2 groups x 2-arms controlled, clinical trial. The intervention will be based on commercially-packaged pasta, which will appear and taste the same; (i) low dose bioactive peptides vs. (ii) high dose bioactive peptides. Inclusion Criteria will be: Male and female non-diabetic adult volunteers at increased estimated CV risk (ESC/EAS SCORE) with SBP 130-139 mmHg and/or DBP 85-90 mmHg); Age included between 40 and 70 years old; Primary prevention for CVD but otherwise in good general health and have had no major illness in the previous 6-months; Volunteer providing their signed and dated informed consent form. Exclusion Criteria will be: Severe medical illness/chronic disease/gastrointestinal pathology (e.g. coeliac disease); Secondary prevention for CVD; Treatment with drugs potentially affecting BP (including antihypertensive drugs) or other related CV risk factors; Consumption of nutraceuticals, botanical extracts or other vitamin supplements; Volunteer diagnosed as being hypertensive A total of 60 participants will be recruited and following adherence to a standardized diet for a 4-week period, will be randomly assigned to complete one of 2 treatment sequences by consuming a prescribed quantity of pasta products for a 4-week period followed by a 4-week washout before random assignment to the 2nd treatment.
The Primary Outcome will be the modification of office blood pressure (assessed by systolic and diastolic BP, pulse and mean pressure (mean of 3 standing \& sitting measures) and 24-hour blood pressure.
Additional outcomes include: Anthropometric parameters (Weight, WC, HC, WC/HC, ICO, BMI), Glucose and Lipid profile (TC, LDL-C, HDL-C, TG, non-HDL cholesterol, risk ratios), Estimated CVD risk changes (EAS/ESC SCORE Charts), Measures of vascular health (FMD, PWA, PWV, Aix), Liver and renal functionality biomarkers, 24-h urine collection at baseline of treatment phase 1 and endpoint of the final phase will be analysed to account for potential confounding of urinary sodium excretion (intake) As required by the GCPs and GLPs, all the SOPs have already been established and all the personnel to be involved in the study is continuously trained in trials with similar outcomes
145 studies on the registry are indexed under Prehypertension; 21 are open to participants now.
This study's planned enrollment of 60 is close to the median of 62 across 127 interventional studies indexed under Prehypertension.
Browse Prehypertension studies →University of Bologna is the lead sponsor of 153 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
100 gr pasta/day, containing around 15 mg bioactive peptides (High content of wheat bioactive peptides)
Other: Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence High->Low)
100 gr pasta/day, containing around 3 mg bioactive peptides
Other: Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence Low->High)
Office blood pressure modification
Systolic, diastolic, pulse, mean arterial pressure, pulse pressure index, mean of 3 consecutive measurement as for the European guidelines on blood pressure measurement suggestion
Time frame: 4 weeks
24-hour blood pressure modification (ABPM)
Twenty-four hour ambulatory blood pressure monitoring (ABPM) will be performed using a non-invasive automatic monitor (Space Labs, model 90207). For ABPM, patients will be instructed to act and work as normal between 6:00 AM and 10:00 PM and rest or sleep between 10:00 PM and 6:00 AM. Readings were obtained automatically at 15-min intervals throughout a 24-h study period. Separate averages will be obtained for the 24-h, daytime (6:00 AM-10:00 PM) and night-time (10:00 PM-6:00 AM) values. The accuracy of the automatic blood pressure readings will be checked against manual readings taken using a standard mercury sphygmomanometer, twice for each ABPM. Blood pressure were was measured with the patient sitting, before the beginning of the ABPM, and after a 5-min rest period. The accuracy test will be repeated after the end of each 24-h ABPM.
Time frame: 4 weeks
Cholesterolemia modification
12-hour fasting Total, LDL, HDL and non HDL-Cholesterol, evaluated with standardized methods
Time frame: 4 weeks
Flow-mediated vasodilation modification
Evaluation of endothelial function by automatic measurement executed with the Vicorder Endopath instrument, already validated in previous publications
Time frame: 4 weeks
Fasting glucose modification
12-hour fasting plasma glucose evaluated with standardized methods
Time frame: 4 weeks
Pulse Wave Velocity modification
Evaluation of arterial stiffness measured as Pulse Wave Velocity and related parameters by the Vicorder instrument, already validated in previous publications
Time frame: 4 weeks
Triglyceridemia modification
12-hour fasting triglyceridemia evaluated by standardized lab methos
Time frame: 4 weeks
Anthropometric measurement changes
Height, weight, body mass index, waist circumference, hip circumference, waist/hip ratio, visceral adiposity index, index of central obesity measured from trained personnel following SOPs
Time frame: 4 weeks
Liver parameters modification
12-hour liver transaminases, gamma-glutamyl-transferase, Lipid Accumulation Product, and Hepatic Steatosis Index evaluated with standardized methods
Time frame: 4 weeks
Renal function parameter modification
12-hour fasting serum uric acid, creatinine, and estimated glomerular filtration rate (CKD-EPI formula) evaluated with standardized methods
Time frame: 4 weeks
This study is status unknown, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Bologna